Aug 10, 2022 / 03:30PM GMT
Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division - Analyst
Good morning, everyone, to the 42nd Annual Canaccord Genuity Global Growth Conference. I'm Kyle Mikson, Life Sciences and Diagnostics at Canaccord, and we are pleased to present Natera here today. Natera is a leader in cell-free DNA-based testing across women's health, oncology and organ health. And with us from the company we have Steve Chapman, CEO; Mike Brophy, CFO. Thanks, guys, for joining us today.
Steven Leonard Chapman - Natera, Inc. - CEO, President & Director
Sure. Thanks for having us.
Michael B. Brophy - Natera, Inc. - CFO
Yes. Thank you.
Questions and Answers:
Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division - AnalystAwesome. So you reported the second quarter results last Thursday, I believe. Great results, I think, almost $200 billion of revenue, solid results across the board. Can you talk about the performance for volume and maybe even ASV across given
Trustpilot
